19 completed. 19 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 19 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow Opiate Dependence: new trials by email Literature Review of Opiate Dependence trials Research Report on Opiate Dependence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Lofexidine on Stress, Craving and Opioid Use Lofexidine, Placebo - Opioid-use Disorder, Opiate Dependence | Phase 2 | Completed | Medical University of South Carolina | 112 | 2019-06-26 | 2025-02-07 |
| Remote Observed Dosing of Suboxone to Improve Clinical Practice Suboxone Remote Observed Dosing, Suboxone Attention Control - Opioid-use Disorder, Opioid Dependence | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 16 | 2019-04-01 | 2023-07-27 |
| Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone extended release naltrexone - Opiate Dependence | Phase 2 / Phase 3 | Completed | University of Pennsylvania | 146 | 2016-01-01 | 2021-01-28 |
| Clinical Efficacy and Serum Proteomic Profiling of Suan-Zao-Ren Tang for Sleep Disturbance During Methadone Maintenance Suan-Zao-Ren Tang, Suan-Zao-Ren Tang placebo - Opiate Dependence | Phase 2 | Completed | China Medical University, Taiwan | 90 | 2013-07-01 | 2014-03-18 |
| Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone injectable naltrexone, placebo comparator - Opiate Dependence, Human Immunodeficiency Virus | Phase 2 / Phase 3 | Completed | University of Pennsylvania | 77 | 2013-06-01 | 2020-11-06 |
| Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia Atomoxetine - Opiate Dependence, Stimulant Dependence | Phase 2 | Completed | Yale University | 90 | 2013-05-01 | 2017-04-27 |
| Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone - Opiate Dependence | Phase 2 | Completed | Paolo Mannelli | 38 | 2012-09-01 | 2016-06-01 |
| Clinical Trial of Integrated Treatment for Pain and Opioid Dependence CBT, Buprenorphine, Educational Counseling - Opiate Dependence, Chronic Pain | Phase 1 / Phase 2 | Completed | Yale University | 90 | 2009-09-01 | 2021-08-02 |
| Employment-Based Depot Naltrexone Clinical Trial II Work Plus Naltrexone Contingency - Opiate Dependence | Phase 2 | Completed | Johns Hopkins University | 38 | 2008-05-01 | 2018-01-23 |
| Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence Enhanced Sexual Risk Management, Standard Sexual Risk Management - Opiate Dependence, HIV Infections | Phase 2 | Completed | Yale University | 22 | 2006-07-01 | 2020-04-03 |
| Employment-Based Depot Naltrexone Clinical Trial employment-based reinforcement - Opiate Dependence | Phase 2 | Completed | Johns Hopkins University | 35 | 2006-05-01 | 2017-12-26 |
| Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction Go Medical Naltrexone implants - Opiate Dependence | Phase 2 / Phase 3 | Completed | University of Oslo | 56 | 2006-01-01 | 2009-05-05 |
| CRAFT Behavior Therapy: Treatment Entry Component Community Reinforcement and Family Training, Treatment Entry Training, 12- step Al/Nar- Anon Facilitation - Drug Addiction, Stimulant Dependence | Phase 2 | Completed | Treatment Research Institute | 180 | 2006-01-01 | 2023-03-28 |
| Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants Clinic-based substance abuse treatment with buprenorphine, Case management and referred substance abuse treatment - Opiate Dependence, HIV Seropositivity | Phase 2 | Completed | Johns Hopkins University | 120 | 2005-11-01 | 2015-04-15 |
| Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1 Tiagabine - Cocaine-Related Disorders, Opiate Dependence | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 80 | 2004-12-01 | 2017-01-12 |
| Brief Introductory Therapy for Opioid Dependence Standard drug counseling, BDRC - Opiate Dependence, HIV Infections | Phase 2 | Completed | Yale University | 51 | 2004-09-01 | 2020-04-02 |
| HIV Risk Reduction and Drug Abuse Treatment in Malaysia Buprenorphine/Subutex, Naltrexone, Drug counseling - Opiate Dependence | Phase 2 | Completed | Yale University | 180 | 2003-04-01 | 2020-03-31 |
| Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence depot naltrexone, Compliance enhancement (CE), BNT - Opiate Dependence | Phase 2 | Completed | New York State Psychiatric Institute | 125 | 2002-06-01 | 2012-10-26 |
| ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids Medisorb naltrexone 75 mg, Medisorb naltrexone 150 mg, Medisorb naltrexone 300 mg - Opiate Dependence | Phase 2 | Completed | Alkermes, Inc. | 27 | 2002-03-01 | 2017-01-11 |
Opioid-Related Disorders (19) · Substance-Related Disorders (4) · HIV Infections (3) · Acquired Immunodeficiency Syndrome (2) · Cocaine-Related Disorders (2) · Alcoholism (1) · Behavior, Addictive (1) · Chronic Pain (1) · HIV Seropositivity (1) · Heroin Dependence (1) · Risk Reduction Behavior (1)
Chemically-Induced Disorders (19) · Mental Disorders (19) · Narcotic-Related Disorders (19) · Substance-Related Disorders (15) · Blood-Borne Infections (4) · Communicable Diseases (4) · Genital Diseases (4) · Immune System Diseases (4) · Immunologic Deficiency Syndromes (4) · Infections (4) · Lentivirus Infections (4) · RNA Virus Infections (4) · Retroviridae Infections (4) · Sexually Transmitted Diseases (4) · Sexually Transmitted Diseases, Viral (4)
Buprenorphine (3) · Naltrexone (3) · vivitrol (3) · Analgesics, Opioid (1) · Atomoxetine Hydrochloride (1) · Buprenorphine, Naloxone Drug Combination (1) · Case Management (1) · Hydromorphone (1) · Naloxone (1) · Practice Management (1) · Tiagabine (1) · lofexidine (1)
Yale University (5) · Johns Hopkins University (3) · University of Pennsylvania (3) · Alkermes, Inc. (1) · China Medical University, Taiwan (1) · Medical University of South Carolina (1) · National Institute on Drug Abuse (NIDA) (1) · New York State Psychiatric Institute (1) · Paolo Mannelli (1) · Treatment Research Institute (1) · University of Oslo (1)
United States (13) · Malaysia (2) · Norway (1) · Russia (1) · Taiwan (1)
George E Woody, MD (2) · Kenneth Silverman, Ph.D. (2) · Bernard L. Silverman, MD (1) · Brenda Curtis, PhD (1) · Edward Nunes, MD (1) · Gerardo Gonzalez, M.D. (1) · Gregory M Lucas, MD, PhD (1) · Helge Waal, MD (1) · Helge Waal, Professor (1) · Kimberly C Kirby, Ph.D. (1) · Kyle Kampman, MD (1) · Lynn E Sullivan, MD (1) · Mahmud Mazlan, M.D. (1) · Marek C Chawarski, Ph.D. (1) · Paolo Mannelli, MD (1)
PMID 21782353, PMID 18586174, PMID 20513828, PMID 20707781, PMID 21320227, PMID 22079773, PMID 27574837, PMID 34737091, PMID 37231479, PMID 40342086
R01DA019497 (2), R01DA010746 (1), R01DA013108 (1), R01DA014718 (1), R01DA018696 (1), R01DA024695 (1), R01DA033670 (1), U34DA045177 (1), U54DA016511 (1)